Factor-IX

Factor IX is a vitamin K–dependent plasma clotting protein (a serine protease zymogen) produced in the liver that plays a central role in the intrinsic coagulation pathway. When activated (IXa) it complexes with factor VIIIa and calcium to activate factor X, promoting fibrin formation. Inherited deficiency causes hemophilia B, an X‑linked bleeding disorder.

Factor IX is called the "Christmas factor" because the clotting protein deficiency that causes hemophilia B was first identified in a patient named Stephen Christmas. When researchers recognized his distinct coagulation defect, they named the condition "Christmas disease" (hemophilia B) and the deficient clotting protein became known as Factor IX. Its absence or dysfunction impairs blood clotting and causes bleeding.

Yes. Factor IX deficiency is hemophilia B (Christmas disease), an X‑linked inherited bleeding disorder caused by low or dysfunctional clotting factor IX. Severity (mild to severe) depends on factor IX activity level; males are most often affected while carrier females may bleed. Treatment typically involves factor IX replacement or newer non‑replacement therapies and supportive care to prevent and control bleeding.

Factor IX is also called the Christmas factor and historically the plasma thromboplastin component (PTC). It’s a vitamin K–dependent serine protease vital to the intrinsic coagulation pathway; inherited deficiency causes hemophilia B, leading to prolonged bleeding and recurrent joint hemorrhages. The “Christmas factor” name comes from the first reported patient with this deficiency.

Factor IX is administered by intravenous infusion of factor IX concentrate (plasma‑derived or recombinant). It’s given as bolus doses or continuous infusion for on‑demand bleeds, perioperative coverage, or regular prophylaxis; dosing is weight‑based and adjusted to target factor‑IX levels. Home infusion is common after training; young children may need central venous access. Extended‑half‑life products reduce infusion frequency.

If factor IX is too high, blood becomes hypercoagulable, raising the risk of venous thromboembolism (DVT/PE), stroke and other arterial clots. Symptoms can include limb swelling, pain or sudden shortness of breath. Causes include inflammation or genetic variants. Evaluation by a hematologist, control of risk factors and, when appropriate, anticoagulation are used to reduce clot risk and identify underlying causes.